Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...

A dentist has highlighted different oral health issues and explained why you should keep an eye on sore throats ...

A dentist has highlighted potential warning signs of oral cancer that people may overlook, including symptoms that could appear without even opening the mouth ...

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

Bristol Myers Squibb on Monday said its experimental drug for a rare form ​of blood cancer improved survival in a late‑stage ...

Roche's shares dropped more than 5% on Monday as the ​Swiss drugmaker failed to show that its promising breast cancer drug ...

Her German shepherd saved her life by detecting cancer in its earliest stage–and now an E-nose can detect tumors with AI chemical training.

H2Ocean proudly participated in the 4th International Conference on Cancer Health Disparities (ICCHD) & 9th Annual ...

The FDA will end a roughly nine-month hiatus of drug-related advisory committee meetings, with plans to convene its first session of 2026 to scrutinize a pair of oncology applications from AstraZen | ...

Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...